Ichiza lesifo seswekile linokuphucula iimpawu zesifo sikaParkinson
I-Lixisenatide, i-glucagon-like peptide-1 receptor agonist (GLP-1RA) yonyango lwesifo sikashukela, iyancipha i-dyskinesia kwizigulane ezinesifo sika-Parkinson ekuqaleni, ngokweziphumo zesigaba se-2 sovavanyo lweklinikhi olupapashwe kwi-New England Journal of Medicine. NEJM) nge-4 ka-Epreli 2024.
Uphononongo, olukhokelwa yiSibhedlele seYunivesithi yaseToulouse (eFransi), lwafumana izifundo ze-156, zahlulwe ngokulinganayo phakathi kweqela lonyango le-lixisenatide kunye neqela le-placebo.Abaphandi balinganisa umphumo weziyobisi usebenzisa i-Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPRSS) Icandelo le-III lamanqaku, kunye namanqaku aphezulu kwisikali esibonisa ukuphazamiseka okukhulu kwentshukumo.Iziphumo zibonise ukuba ngenyanga ye-12, i-MDS-UPDRS inxalenye ye-III iyancipha ngamanqaku e-0.04 (ebonisa ukuphuculwa okuncinci) kwiqela le-lixisenatide kwaye yanda ngamanqaku e-3.04 (ebonisa ukunyuka kwesifo) kwiqela le-placebo.
Umhleli we-NEJM wangoku waphawula ukuba, kumphezulu, ezi datha zibonisa ukuba i-lixisenatide ikuthintele ngokupheleleyo ukwanda kweempawu zesifo sika-Parkinson kwisithuba seenyanga ezili-12, kodwa oku kunokuba yimbono enethemba eligqithisileyo.Zonke izikali ze-MDS-UPDRS, ezibandakanya iCandelo le-III, zizikali ezihlanganisiweyo eziqulethwe ngamacandelo amaninzi, kwaye ukuphuculwa kwenxalenye enye kunokuchasana nokuwohloka kwenye.Ukongeza, omabini amaqela olingo anokuthi axhamle nje ngokuthatha inxaxheba kulingo lwezonyango.Nangona kunjalo, umahluko phakathi kwamaqela amabini olingo ubonakala uyinyani, kwaye iziphumo zixhasa isiphumo se-lixisenatide kwiimpawu zesifo sikaParkinson kunye nekhosi yesifo esinokubakho.
Ngokuphathelele ukhuseleko, iipesenti ze-46 zezifundo eziphathwe nge-lixisenatide ziye zafumana isicaphucaphu kunye neepesenti ze-13 zaziva zigabha.I-NEJM yomhleli iphakamisa ukuba iziganeko zeziphumo ebezingalindelekanga zinokuthintela ukusetyenziswa ngokubanzi kwe-lixisenatide kunyango lwe-Parkinson's, kwaye ngoko ke ukuphononongwa okuqhubekayo ukuncitshiswa kwethamo kunye nezinye iindlela zoncedo ziya kubaluleka.
"Kolu vavanyo, ukuhlukana kwamanqaku e-MDS-UPDRS kwakubaluleke kakhulu kodwa kuncinci emva kweenyanga ze-12 zonyango kunye ne-lixisenatide. Ukubaluleka kolu vavanyo alukho kubukhulu benguqu, kodwa kwinto ebonisa ngayo."Umhleli okhankanywe ngasentla ubhala, "Inkxalabo enkulu kwizigulane ezininzi ze-Parkinson akusiyo imeko yabo yangoku, kodwa ukwesaba ukuqhubela phambili kwesifo. Ukuba i-lixisenatide iphucula amanqaku e-MDS-UPDRS ngamanqaku amaninzi e-3, ngoko ixabiso lonyango leyeza linokuthi lilinganiselwe. ngokukodwa xa kunikwe iziphumo zayo ezimbi, kwelinye icala, ukuba ukusebenza kwe-lixisenatide kuyanda, ukwandisa amanqaku ngamanye ama-3 ngonyaka kwithuba le-5 ukuya kwiminyaka eyi-10 okanye ngaphezulu, ngoko oku kunokuba lunyango oluguqula ngokwenene inyathelo elilandelayo ngokucacileyo kukuqhuba iimvavanyo zexesha elide."
Iphuhliswe ngumenzi weziyobisi waseFransi uSanofi (SNY.US), i-lixisenatide yamkelwe yi-US Food and Drug Administration (FDA) kunyango lwe-2 yesifo seswekile ngo-2016, iyenza i-5th GLP-1RA ukuba ithengiswe kwihlabathi jikelele.Ukujonga idatha ukusuka kwizilingo zeklinikhi, ayisebenzi kakuhle ekunciphiseni i-glucose njengabalingani bayo be-liraglutide kunye ne-Exendin-4, kunye nokungena kwayo kwimarike yase-US kwafika emva kwexesha labo, okwenza kube nzima ukuba imveliso ifumane indawo.Ngo-2023, i-lixisenatide yarhoxiswa kwimarike yase-US.USanofi ucacisa ukuba oku kwakungenxa yezizathu zorhwebo kunemiba yokhuseleko okanye ukusebenza kakuhle nechiza.
Isifo sikaParkinson sisifo se-neurodeergenerative esenzeka ikakhulu kubantu abadala abaphakathi kunye nabasele bekhulile, eyona nto iphawuleka ngokungcangcazela, ukuqina kunye neentshukumo ezicothayo, ngesizathu esingaziwayo.Okwangoku, undoqo wonyango lwesifo sikaParkinson lunyango lokubuyisela i-dopaminergic, olusebenza ngokuyintloko ukuphucula iimpawu kwaye alunabungqina obubambekayo bokuchaphazela ukuqhubeka kwesifo.
Izifundo ezininzi zangaphambili zifumene ukuba i-GLP-1 receptor agonists inciphisa ukudumba kwengqondo.I-Neuroinflammation ikhokelela kwilahleko eqhubekayo yeeseli zengqondo ezivelisa i-dopamine, eyona nto iphambili yesifo sikaParkinson.Nangona kunjalo, kuphela i-GLP-1 receptor agonists enokufikelela kwingqondo esebenzayo kwisifo sikaParkinson, kwaye kutsha nje i-semaglutide kunye ne-liraglutide, ezaziwa kakhulu ngeziphumo zabo zokuncipha kobunzima, azizange zibonise amandla okunyanga isifo sikaParkinson.
Ngaphambili, uvavanyo oluqhutywe liqela labaphandi kwi-Institute of Neurology kwiYunivesithi yaseLondon (e-UK) lufumene ukuba i-exenatide, efana ne-lixisenatide, iphucule iimpawu zesifo sikaParkinson.Iziphumo zovavanyo zibonise ukuba kwiiveki ze-60, izigulane eziphathwe nge-exenatide zine-1-point yokunciphisa amanqaku abo e-MDS-UPDRS, ngelixa abo baphathwa nge-placebo babenokuphuculwa kwe-2.1-point.Iphuhliswe ngokudibeneyo ngu-Eli Lilly (LLY.US), inkampani enkulu yamayeza yase-US, i-exenatide yi-agonist yokuqala ye-GLP-1 ye-receptor yehlabathi, eyayilawula imarike iminyaka emihlanu.
Ngokwezibalo, ubuncinci ii-agonists ezintandathu ze-GLP-1 receptor ziye zavavanywa okanye zivavanywa ngoku ukusebenza kwazo ekunyangeni isifo sikaParkinson.
Ngokutsho koMbutho weHlabathi weParkinson, ngoku kukho izigidi ezi-5.7 zabaguli besifo sikaParkinson kwihlabathi liphela, malunga ne-2.7 yezigidi eTshayina.Ngo-2030, iChina iya kuba nesiqingatha sabemi behlabathi beParkinson.Imakethi yehlabathi yesifo sikaParkinson iya kuba nentengiso ye-RMB 38.2 yeebhiliyoni ngo-2023 kwaye kulindeleke ukuba ifikelele kwi-RMB 61.24 yeebhiliyoni ngo-2030, ngokutsho kweDIResaerch (DIResaerch).
Ixesha lokuposa: Apr-24-2024
.png)
